David Browning

OBN Chairman & CEO, Fixed-Phage Ltd

David joined OBN as a non-executive director in December 2018, becoming Chairman in September 2020. As CEO of Fixed Phage he is focussing on playing an active role in addressing the increasing prevalence of antibiotic resistance. The proprietary, sustainable Fixed Phage technology localises and stabilises phages, enabling their widespread practical application. He has advised numerous successful businesses across health, life-sciences and nanotechnology, applying 38 years of healthcare innovation experience to improve standards of care and health economic outcomes. Previous roles include CEO of Oxford Cancer Biomarkers, Senior Vice President, Development and Innovation of the BioCity Group and Managing Director of MediCity, supporting new life science business creation and accelerating growth. David was CEO of disruptive innovation ventures within Philips, incorporating companion diagnostics into the Philips Digital Pathology business. He has successfully driven innovation within Amersham International, J&J, IGEN International and Oxonica Healthcare, an Oxford University spin-out. David commenced his career as a Biomedical Scientist within the NHS, gaining his MSc in Biochemical Immunology. David is actively involved in sport, representing Great Britain in Cross Triathlon and is engaged with coaching and inspiring young people to improve their wellbeing through positive lifestyle choices.